Jo Jung Ki, Kim Hwanik, Bang Woo Jin, Oh Cheol Young, Cho Jin Seon, Shim Myungsun
Department of Urology, College of Medicine, Hanyang University, Seoul, Korea.
Department of Urology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
Int Neurourol J. 2023 Jun;27(2):116-123. doi: 10.5213/inj.2346008.004. Epub 2023 Jun 30.
To compare improvement of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia in diabetic versus nondiabetic patients after transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP).
The medical records of 437 patients who underwent TURP or HoLEP at a tertiary referral center from January 2006 to January 2022 were retrospectively analyzed. Among them, 71 patients had type 2 diabetes. Patients in the diabetic mellitus (DM) and non-DM groups were matched 1:1 according to age, baseline International Prostate Symptom Score (IPSS), and ultrasound measured prostate volume. Changes in LUTS were assessed at 3 months after surgery using IPSS and evaluated by categorizing patients according to prostatic urethral angulation (PUA; <50° vs. ≥50°). Medication-free survival after surgery was also investigated.
No significant differences were noted between the DM and non-DM groups in baseline characteristics except for comorbidities (i.e., hypertension, cerebrovascular disease, and ischemic heart disease, P=0.021, P=0.002, and P=0.017, respectively) and postvoid residual urine volume (115±98 mL vs. 76±105 mL, P=0.028). Non-DM patients showed significant symptomatic improvement regardless of PUA, while DM patients demonstrated improvement in obstructive symptoms only in those with large PUA (≥51°). Among patients with small PUA, DM patients had worse medication-free survival after surgery compared to controls (P=0.044) and DM was an independent predictor of medication reuse (hazard ratio, 1.422; 95% confidence interval, 1.285-2.373; P=0.038).
DM patients experienced symptomatic improvement after surgery only in those with large PUA. Among patients with small PUA, DM patients were more likely to reuse medication after surgery.
比较经尿道前列腺切除术(TURP)或钬激光前列腺剜除术(HoLEP)后,糖尿病患者与非糖尿病患者良性前列腺增生所致下尿路症状(LUTS)的改善情况。
回顾性分析2006年1月至2022年1月在一家三级转诊中心接受TURP或HoLEP的437例患者的病历。其中,71例患者患有2型糖尿病。糖尿病(DM)组和非DM组患者根据年龄、基线国际前列腺症状评分(IPSS)和超声测量的前列腺体积进行1:1匹配。术后3个月使用IPSS评估LUTS的变化,并根据前列腺尿道角度(PUA;<50°与≥50°)对患者进行分类评估。还调查了术后无药物生存情况。
除合并症(即高血压、脑血管疾病和缺血性心脏病,P分别为0.021、0.002和0.017)和残余尿量(115±98 mL对76±105 mL,P = 0.028)外,DM组和非DM组在基线特征方面无显著差异。非DM患者无论PUA如何均显示出明显的症状改善,而DM患者仅在PUA较大(≥51°)的患者中梗阻症状有所改善。在PUA较小的患者中,DM患者术后无药物生存情况比对照组差(P = 0.044),且DM是药物复用的独立预测因素(风险比,1.422;95%置信区间,1.285 - 2.373;P = 0.038)。
DM患者仅在PUA较大的患者中术后症状得到改善。在PUA较小的患者中,DM患者术后更有可能复用药物。